ST Germain D J Co. Inc. lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 18.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 6,827 shares of the biopharmaceutical company’s stock after acquiring an additional 1,060 shares during the period. ST Germain D J Co. Inc.’s holdings in Gilead Sciences were worth $427,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of GILD. Bank of New York Mellon Corp lifted its holdings in shares of Gilead Sciences by 199,789.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock valued at $2,420,587,000 after purchasing an additional 31,335,030 shares in the last quarter. Capital Research Global Investors boosted its stake in Gilead Sciences by 22.5% in the 3rd quarter. Capital Research Global Investors now owns 69,854,968 shares of the biopharmaceutical company’s stock valued at $5,393,502,000 after purchasing an additional 12,818,301 shares during the period. Skandinaviska Enskilda Banken AB publ boosted its stake in Gilead Sciences by 285.0% in the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 3,998,024 shares of the biopharmaceutical company’s stock valued at $308,688,000 after purchasing an additional 2,959,697 shares during the period. TIAA CREF Investment Management LLC boosted its stake in Gilead Sciences by 21.1% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 10,241,394 shares of the biopharmaceutical company’s stock valued at $790,738,000 after purchasing an additional 1,786,881 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in Gilead Sciences by 63.1% in the 3rd quarter. Renaissance Technologies LLC now owns 4,489,648 shares of the biopharmaceutical company’s stock valued at $346,646,000 after purchasing an additional 1,737,248 shares during the period. 77.76% of the stock is currently owned by hedge funds and other institutional investors.
GILD stock traded down $0.99 during midday trading on Thursday, hitting $65.99. The company’s stock had a trading volume of 71,586 shares, compared to its average volume of 7,378,524. The stock has a market capitalization of $86.36 billion, a PE ratio of 10.71, a price-to-earnings-growth ratio of 4.20 and a beta of 1.19. Gilead Sciences, Inc. has a 12 month low of $60.32 and a 12 month high of $82.71. The company has a current ratio of 3.36, a quick ratio of 3.29 and a debt-to-equity ratio of 1.09.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.70 by ($0.26). The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.52 billion. Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The business’s revenue was down 2.6% compared to the same quarter last year. During the same period last year, the company posted $1.78 earnings per share. On average, research analysts predict that Gilead Sciences, Inc. will post 6.23 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 28th. Investors of record on Friday, March 15th will be given a $0.63 dividend. The ex-dividend date of this dividend is Thursday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.57. This represents a $2.52 annualized dividend and a yield of 3.82%. Gilead Sciences’s dividend payout ratio is 37.07%.
GILD has been the subject of several recent analyst reports. ValuEngine upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, December 1st. BidaskClub raised Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, November 8th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, November 14th. Oppenheimer reiterated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, November 14th. Finally, Citigroup restated a “buy” rating and issued a $100.00 target price on shares of Gilead Sciences in a report on Tuesday, February 5th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $83.59.
In other news, Director John C. Martin sold 50,000 shares of the stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $71.20, for a total transaction of $3,560,000.00. Following the transaction, the director now directly owns 2,877,762 shares of the company’s stock, valued at approximately $204,896,654.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Gayle E. Wilson sold 19,068 shares of the company’s stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $67.08, for a total value of $1,279,081.44. Following the completion of the sale, the director now owns 143,567 shares of the company’s stock, valued at $9,630,474.36. The disclosure for this sale can be found here. 1.16% of the stock is owned by corporate insiders.
WARNING: “Gilead Sciences, Inc. (GILD) Position Lifted by ST Germain D J Co. Inc.” was originally published by Zolmax and is the property of of Zolmax. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://zolmax.com/investing/gilead-sciences-inc-gild-position-lifted-by-st-germain-d-j-co-inc/2917369.html.
Gilead Sciences Profile
Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Article: 12b-1 Fees
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.